How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology, and Vaccines
Many CDMOs outsource their nanoparticle supply chain, but in house manufacturing of nanoparticles at CDMOs is anticipated to create new market opportunities.
Related Content
New Strategies for a Better Glycosylation Profile
January 22nd 2025Article
Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality.
